Compare Nutrien Ltd (NTR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Novo Nordisk A/S — how do they compare? Nutrien Ltd trades at $80.84 (market cap $38.66B), while Novo Nordisk A/S trades at $45.1 (market cap $198.57B). The key difference: Novo Nordisk A/S is far larger — about 5.1× Nutrien Ltd's market cap, and Novo Nordisk A/S pays the higher dividend (4.03%). Which is the better fit depends on your goals.
| NTR | NVO | |
|---|---|---|
Market Cap | $38.66B | $198.57B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $63.98 |
52-Week Low | $53.64 | $35.29 |
Enterprise Value | $50.46B | $213.37B |
Dividend Yield | 2.73% | 4.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $80.68, up 1.52% today, near the analyst high target of $81.00. The stock shows a bullish technical trend with strong moving averages, though RSI levels indicate overbought conditions. Recent Q2 2026 earnings missed EPS estimates but beat on revenue, driven by higher fertilizer prices. The company maintains a moderate buy consensus with 61% of analysts recommending buys, supported by institutional accumulation like BlackRock's $220.94 million purchase in Q2 2026.
Outlook remains positive due to structural advantages in North American nitrogen assets and long-term agricultural demand, but risks include cyclical earnings, sulfur cost pressures, and volume constraints. The current price above the $76.17 consensus target suggests limited near-term upside, requiring monitoring of Q3 2026 results and cost management.
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
